Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jul 14 2023 | JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients Industry News In The News Industry Read More Jun 22 2023 | Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Industry News In The News Industry Read More Jun 16 2023 | U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label Industry News In The News Industry Read More Jun 16 2023 | Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services Industry News In The News Industry Read More Jun 5 2023 | Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Jul 14 2023 | JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients Industry News In The News Industry Read More
Jun 22 2023 | Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Industry News In The News Industry Read More
Jun 16 2023 | U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label Industry News In The News Industry Read More
Jun 16 2023 | Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services Industry News In The News Industry Read More
Jun 5 2023 | Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care Industry News In The News Industry Read More
